Director, Prescription Drugs and Biologics, Corporate Transactions, Enforcement, Hyman, Phelps & McNamara, PC
Kurt R. Karst provides regulatory counsel to pharmaceutical manufacturers on Hatch-Waxman patent and exclusivity, drug development, pediatric testing, and orphan drugs, including lifecycle management, approval, post-marketing, and exclusivity issues. He is co-founder and primary author...
Read More →